Challenge:
A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases. Alacrita was commissioned to use its experience in cell therapeutics to perform a technical due diligence on the company to highlight any key risks and to propose mitigation strategies.
Solution:
Alacrita reviewed information provided by the client and compiled a report, analysing the following key areas in the technology platform and therapeutic programs:
- Therapeutic focus
- Molecular targets
- Scientific rationale
- Pre-clinical data
- Regulatory status/correspondence
- CMC issues
- Clinical development plans
- IP
- Competitive landscape
- Market opportunity
- Company infrastructure.
Upon further discussion with the target company on issues raised during the initial review and analysis, we finalised our report to the investor summarising the above points and outlining the key risks in the programs. The company agreed that the identified risks were indeed material, and one of the predicted issues occurred shortly after our report was finalised.